Circulating Tumor Cells in Solid Tumors
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
2 other identifiers
observational
206
1 country
1
Brief Summary
The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer. Develop a database and a sample repository where future analysis could be done.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 9, 2011
CompletedFirst Submitted
Initial submission to the registry
May 15, 2017
CompletedFirst Posted
Study publicly available on registry
May 22, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 16, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 16, 2021
CompletedSeptember 28, 2022
September 1, 2022
9.2 years
May 15, 2017
September 27, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Documentation of the Quality of CTCs from Patients with Solid Tumors
Enumeration of participants' circulating solid tumor cells
Through study completion, an average of 5 years
Documentation of the Characterization of CTCs from Patients with Solid Tumors
Characterization of participants' circulating solid tumor cells
Through study completion, an average of 5 years
Interventions
Eligibility Criteria
Patients with cancerous solid tumors
You may qualify if:
- Age ≥ 18 years of age
- Biopsy proven solid tumor malignancy
- Seen at UNC Chapel Hill Hospital and Health Care System
- Consents to abstraction of their medical records
- Signed an institutional review board (IRB)-approved informed consent document for this protocol
You may not qualify if:
- \< 18 years of age
- Dementia, altered mental status, incarceration or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Radiation Oncology Clinic - UNC Cancer Hospital
Chapel Hill, North Carolina, 27599, United States
Related Publications (1)
Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, Goldman E, Weiss J, Grilley-Olson J, Patel S, Zanation A, Hackman T, Blumberg J, Patel S, Thorp B, Weissler M, Yarbrough W, Sheets N, Mendenhall W, Tan XM, Gupta GP. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol. 2020 Apr 1;38(10):1050-1058. doi: 10.1200/JCO.19.02444. Epub 2020 Feb 4.
PMID: 32017652DERIVED
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lisa A Carey, MD
University of North Carolina
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2017
First Posted
May 22, 2017
Study Start
December 9, 2011
Primary Completion
February 16, 2021
Study Completion
February 16, 2021
Last Updated
September 28, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share